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Background: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been
established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical
features and predictors of survival in these patients.
Methods: We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated
with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated
by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to
adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied
included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and
the Cox regression model was used to identify potential predictors of outcome.
Results: The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8).
In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of
RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis
were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and
alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate
analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled
primary HCC.
Conclusions: Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated
with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy.
Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors.
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Extrahepatic metastases occurring in hepatocellular carcin-
oma (HCC) are now observed more frequently because of
the prolonged survival of HCC patients. Despite advances
in treatment modalities and surgical techniques in recent
years, the management of recurrence or distant metastasis
remains a critical problem in treatment of HCC [1]. Intra-
hepatic recurrence can be controlled by several treatment* Correspondence: zeng.zhaochong@zs-hospital.sh.cn
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unless otherwise stated.modalities, such as repeated hepatectomy, transcatheter
arterial chemoembolization (TACE), radiotherapy (RT),
percutaneous ethanol injection therapy (PEIT), and liver
transplantation [2,3]. While treatment modalities of intra-
hepatic recurrence are well documented in the literature,
there is much less information available that focuses on
treatment strategies for extrahepatic metastasis. Although
the adrenal glands are the second most frequent organ of
extrahepatic metastasis from HCC, there are no definitive
guidelines for treatment of these conditions [4-7]. In 2005,
we retrospectively studied the effect of RT on the adrenal
metastatic lesions in 22 HCC patients treated with two-td. This is an Open Access article distributed under the terms of the Creative
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in radiotherapy technology involving precise delivery of
focused high-doses on target volume, or sparing organs at
risk, it is desired to update our understanding on the RT
on the adrenal metastases in an expanded HCC cohort.Methods
Source of patient and clinical data
A retrospective review of the medical records of 55 pa-
tients who underwent RT for adrenal metastases of HCC
between January 2001 and August 2011 at the Zhongshan
Hospital of Fudan University was performed. The patients’
characteristics from these records are summarized in
Table 1. Approval for this study was obtained from the
Zhongshan Hospital Research Ethics Committee.Diagnosis of HCC and adrenal metastasis
The diagnosis of HCC was confirmed by histology of a
surgical specimen or by clinical diagnosis. For the latter,
a positive diagnosis met the following criteria issued by the
Chinese Liver Cancer Association in 1999 [8]. First, the
serum alpha-fetoprotein (AFP) level should be >400 mg/l,
to rule out patients with active liver disease, embryonal
malignant teratoblastomas of the testes or ovary, or other
malignant tumors metastasizing to the liver. Additionally,
the tumor should have a characteristic appearance by one
of several HCC imaging methods. Second, if the serum
AFP level is <400 mg/l, the characteristic intrahepatic le-
sion should be confirmed by two imaging methods. To ex-
clude patients with metastatic tumors from the digestive
system or intrahepatic cholangiocarcinoma, the status of
carcinoembryonic antigen or carbohydrate antigen 19.9
(CA19.9) should be negative for those with negative AFP
levels. Of the patients in this study, 35 patients were con-
firmed by pathology and 20 patients were clinically diag-
nosed. All these patients had a Karnofsky performance
scale score of at least 80. The Child-Pugh classification,
reflecting liver function, was scored based on the levels of
serum bilirubin and albumin, prothrombin time prolonga-
tion, presence or absence of ascites, and encephalopathy.
Adrenal gland metastasis was primarily detected by
abdominal-pelvic enhanced computed tomography (CT)
imaging (37 patients) and magnetic resonance imaging
(MRI) (18 patients). A positive diagnosis was reached in
cases in which the interval appearance of an adrenal
mass on serial images was considered to represent
metastatic disease [7]. Symptoms included back pain
(32 patients) and epigastric/upper quadrant visceral
pain (10 patients). Other symptoms such as hyperten-
sion, Cushing syndrome or electrolyte imbalance, which
might relate to the abnormal function of the adrenal
gland, were not observed in the cohort.Treatment of primary HCC
Intrahepatic primary tumors were treated with TACE
alone (20 patients) or resection followed by TACE (31
patients). Surgical resection focused on the removal of
only the intrahepatic primary tumors. The TACE proced-
ure comprised a combination of targeting chemotherapy
with various drugs, including 5-fluorouracil (5-FU), cis-
platin (DDP), and mitomycin C (MMC). There were no
standard protocols for the treatment. Most of these pa-
tients were treated two to six cycles of TACE. Four pa-
tients received liver transplantations. There were 3
patients in this cohort receiving target drug, sorafenib
after adrenal metastasis irradiation.
External beam radiotherapy (EBRT)
If the patients’ intra-hepatic lesions remained to be
stable more than 2 months, radiotherapy to adrenal me-
tastasis will be conducted. Intrahepatic lesions and ad-
renal metastasis were irradiated simultaneously in 3
patients. Patients received limited-field RT using a linear
accelerator (SIEMENS) with a 6- or 15-MV (depending
on tumor location and depth) photon beam strictly focused
on the adrenal lesion. In our study, there were 29 patients
treated before 2005 who received two-dimensional (2-D)
conventional RT, and the prescribed dose was rarely more
than 54 Gy. After 2005, there were 26 patients who were
treated with three-dimensional conformal or intensity-
modulated RT (3-D CRT or IMRT).
The patients were positioned in supine and immobi-
lized using a vacuum bag to improve the reproducibility
of daily treatments. If the adrenal metastatic lesions were
adjacent to the liver, the patients received training in
respiration to reduce the amplitude, increase the fre-
quency and minimize tumor movement before the initi-
ation of RT. The respiratory movement was estimated
during simulation, and if it was >1.0 cm, abdominal
compression was applied to minimize the movement [7].
Images for CT-based isocentric, multiportal, or 3-D
CRT were taken with the patient lying in treatment
couch. The CT scan slices were obtained at intervals of
3 mm from the superior to inferior extent of the simu-
lated fields. CT images were directly transmitted to the
3-D planning system. The gross tumor volume (GTV)
was defined as the volume of the radiographically visible
adrenal lesion. The clinical target volume (CTV) was
created by adding a 0.4-cm margin around the visible
metastatic tumor. The planning target volume (PTV)
was determined as the CTV plus 0.5-0.7 cm. The me-
dian tumor dose was 50 Gy (range of 26-62 Gy) in daily
2.0 Gy fractions, five times per week. Factors that indi-
cated the need for a reduced dose were considered such
as progressive primary disease, poor performance status,
severe adverse effects, and patient inconvenience during
EBRT. The scheduled doses depended on factors relating
Table 1 Patients and tumor characteristics
Independent variable Patients Kaplan-Meier survival Univariate analysis Multivariate analysis
n Median (months) P P
Age (yr) .114 n.s.
≤50 23 12.63 ± 4.26
>50 32 13.63 ± 4.88
Gender .411 n.s.
Male 52 13.63 ± 1.48
Female 3 7.27 ± 0.63
γ-GT 6 missing .008 n.s
<150 33 17.80 ± 6.51
≥150 16 5.57 ± 3.53
AFP level (μg/ml) .027 n.s
<400 33 15.90 ± 2.62
≥400 22 5.57 ± 2.01
Child-Pugh classification .043 n.s
A 45 15.27 ± 1.63
B 10 5.53 ± 2.43
Maximal diameter of intrahepatic tumors (mm) .074 n.s
≤80 33 15.13 ± 3.32
>80 22 8.87 ± 1.46
Number of intrahepatic tumor(s) .000 .042
Solitary 45 15.90 ± 2.61
Multiple (>2) 10 5.57 ± 3.30
Interval .422 n.s.
Synchronous 8 8.87 ± 1.22
Metachronous 47 13.63 ± 1.52
Resection including liver transplantation for intrahepatic tumors .483 n.s.
Yes 35(4) 15.90 ± 2.38
No 20 10.53 ± 3.17
Additional organ metastasis .001 .00
Yes 9 4.47 ± 0.45
No 46 15.27 ± 1.63
Metastatic adrenal tumor size (mm) .476 n.s.
<50 21 15.13 ± 4.40
≥50 34 13.20 ± 2.02
Location of adrenal lesion .614 n.s.
Single adrenal 47 13.63 ± 1.42
Both 8 9.27 ± 5.33
Radiation dose (Gy) .102 .059
≥54 18 21.27 ± 8.46
<54 37 12.93 ± 2.15
Primary HCC .00 .003
Controlled 38 17.80 ± 4.77
Uncontrolled 17 9.77 ± 2.94
Response to RT 5 missing .017 n.s
PR 32 17.80 ± 8.28
SD 18 12.63 ± 2.79
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spinal cord, liver, stomach, small bowl and kidney were
the key consideration. Adverse effects, such as gastro-
intestinal reactions, the volume of irradiated kidneys,
and the status of intrahepatic tumors and distant metas-
tasis, were taken into account. The schedule prescribed
doses were no less than 46 Gy. The normal tissue dose
limitation are listed as follows: The maximum dose of
the spinal cord did not exceed 45 Gy. The whole liver
mean dose did not exceed 30Gy. The maximum dose of
the small bowl did not exceed 54 Gy and V50 ≤ 5%,
V40 ≤ 30%. The maximum dose of the stomach did not
exceed 54 Gy and V45 < 50%. The mean dose of two kid-
neys did not exceed 15Gy and V20 ≤ 33%, V28 ≤ 20%,
V12 ≤ 55%.
Follow up and assessment of response and toxicity
Before treatment, an evaluation of medical history, phys-
ical examination, complete blood cell count, and liver
and kidney function tests (Roche Diagnostics, Indian-
apolis, IN, USA) were performed. Clinical monitoring
was performed every 1 − 2 weeks. After RT, the patients
were periodically evaluated by CT or MRI in an out-
patient clinic at our institute or at a hospital selected by
the patient.
Patients were advised of the need for follow up 6 −
12 weeks after the completion of RT. Responses to RT
were evaluated at that time by abdominal CT (enhanced
or unenhanced) or MRI. Patients were monitored every
3 months thereafter. Local responses were classified
according to the Response Evaluation Criteria in Solid
Tumors with modifications [9].
Serum AFP levels were determined using an electro-
chemiluminescence immunoassay (Roche Diagnostics).
For AFP-positive patients, this determination was re-
peated at the first follow-up visit. The changes in AFP
levels were compared approximately 3 months apart,
from pre-RT to 6 weeks after completion of RT. The
threshold for an AFP decline was either a serum concen-
tration of <20 mg/l or a >10% reduction in the serum
level [10].
The visual analogue scale of pain was used to assist
patients describing the intensity of pain experienced. On
the numerical rating scale, the patient was asked to iden-
tify a position between 0 (no pain) to 10 (worst pain im-
aginable) [11]. Partial pain relief (partial response or PR)
was defined as a decrease of the initial pain score by at
least two points without increased analgesic dosage.
Complete pain relief (complete response) was defined as
a decrease to 0 on the pain scale without analgesic in-
crease. Progression after response was defined as (1) an
increase in pain with return to the initial pain score or
higher without analgesic increase or (2) an increase in
administration of an analgesic agent from a lower phaseto phase 3 or 4, irrespective of the pain score. All of the
patients in this study filled out a pain score form before
and after treatment. Responses were evaluated within
1 week of completion of EBRT.
Toxicity assessment
Acute and late reactions were scored according to the
Common Terminology Criteria for Adverse Events ver-
sion 3.0 (CTCAE) of the National Cancer Institute
(USA) [12]. Complete blood cell counts and routine
chemistry determinations were performed twice a week
during the course of treatment.
Statistical analyses
The overall survival period was defined from the date of
diagnosis of adrenal metastases to the date of death or
the last follow-up appointment. Kaplan-Meier curves
were generated to analyze overall survival. The Cox re-
gression model was used to detect associations between
survival and serum AFP and γ-GT levels, intrahepatic
tumor status (tumor size and number), Child-Pugh classi-
fication, and radiation dose additional organ metastasis,
and primary HCC status (controlled or uncontrolled).
Statistical analyses were performed using the Statistical
Package for Social Sciences, version 13.0. P values <0.05
were considered statistically significant.
Results
Patient characteristics
The demographic characteristics of the study patients are
listed in Table 1. The cohort included 52 men and 3
women with a mean age of 54.4 ± 11.0 years (range, 34 −
82 years). Pretreatment variables showing an effect on sur-
vival, including demographics, clinical laboratory tests,
tumor characteristics, and treatment information for pa-
tients, are also listed in Table 1.
In total, 63 lesions in 55 patients received RT. However,
for six of the lesions, CT or MRI documentation after RT
was lacking, and therefore, the following data are expressed
for the remaining 57 documented lesions. In 68.4% of the
lesions (39/57), a PR (include 1 got CR) was achieved, and
stable disease (SD) was reached in 31.6% (18/57). Serum
AFP levels were abnormally high before RT in 40 patients.
By comparison to pretreatment serum levels, an AFP de-
cline was seen in 19 patients (47.5%), a stabilization was
seen in 9 patients (22.5%), and 12 patients (30.0%) had
increased AFP levels. Of all the patients, the median
survival time was 13.6 months, and the 1-year survival
rate was 58.7%, two-year survival rate was 32.3%. The
3 patients receiving target therapy, whose survival time
were 12.6, 9.2, 24.1 months, respectively.
Before RT, there were 42 patients with pain that was
always rated as mild on the visual scale (≤3) with or
without treatment with non-narcotic analgesic agents.
Figure 1 Overall survival curves for the 55 patients in the study.
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after completion of RT (Table 2).
Pretreatment variables and results of univariate and
multivariate analyses
The median survival time of the 55 patients was 13.6
months (Figure 1). Relative to pretreatment variables,
the Kaplan-Meier survival analysis showed that the fol-
lowing variables were related to unfavorable overall sur-
vival: multiple intrahepatic tumors, higher serum AFP
and γ-GT levels, liver function Child-Pugh classification
B or higher, metastasis to additional organ(s), uncon-
trolled primary HCC, and a poor response to RT.
Multivariate analysis indicated that unfavorable pretreat-
ment predictors were associated with multiple intrahepa-
tic tumors (P = .042) (Figure 2A), metastasis to additional
organ(s) (P = .00) (Figure 2B), and uncontrolled primary
HCC (P = .003) (Figure 2C) as also shown in Table 1.
Failure patterns
Four patients’ adrenal lesions (four lesions) relapsed
after RT. The time of relapse ranged from 6 − 11 months
(median time was 9 months) and the prescribed doses
for treatment were 40 − 50 Gy. One patient received a
second-course of RT and achieved PR.
At the time of the retrospective analysis, 42 of the pa-
tients died. However, none of these deaths resulted from
adrenal metastasis-related complications. Liver failure
caused by primary tumor progression (upper digestive
tract bleeding and hydroperitoneum) resulted in 35
deaths. Other deaths were the consequence of lung me-
tastasis (four patients), abdominal lymph node metasta-
sis and related complications (two patients), and brain
metastasis (one patient).
Adverse effects
Side effects (acute/long-term toxicity) that were ob-
served in patients during or after the RT treatment are
listed in Table 3. The most acute common adverse ef-
fects were loss of appetite and nausea during the proced-
ure. These effects usually occurred at the end of the
therapy, and most patients did not need fluid infusion.
Thrombocytopenia was observed in 32 patients and was
associated with the presence of poorer liver function andTable 2 Dose effect for tumor volume and pain relief
Radiation
dose (Gy)
Patients (n) Response to
RT(PR) 5 missing
Pain relief
26 1 0/1 -
36 1 0/1 -
40-49 10 7/10 7/7
50 25 13/22 19/19
54-62 18 12/16 16/16hypersplenism. Incidence of acute side effects of 29 pa-
tients who received two-dimensional conventional RT is
similar to those of patients received 3-D CRT or IMRT.
One patient stopped to receive RT due to digestive tract
bleeding after receiving 26 Gy radiation. One patient ter-
minated RT because of low platelet count, and three pa-
tients terminated RT by themselves because of anorexia.
Two patients had increased serum levels of liver en-
zymes that were usually less than three times the upper
normal limit. The increasing of serum liver enzymes oc-
curred during RT for one patient and 2 months after RT
for the other patients. In the former, the prescribed dose
was completed after a 2-week rest period. Mean liver
doses were not excess 25 Gy for the two patients.
Long-term toxicity including mild to moderate hepatic
dysfunction(17/55), abdominal pain and diarrhea(15/55),
transient albuminuria(2/55) and Mild elevation of blood
urea nitrogen and creatinine(1/55) was observed in this
cohort. Incidence of late side effects in patients who re-
ceived 2-D conventional RT is also similar to those in
patients received 3-D CRT or IMRT. No clinical symptoms
of radiation-induced nephritis (hypertension, anemia, ele-
vated blood urea nitrogen and creatine levels, or albumin-
uria), and digestive tract injury (intestinal perforation and
stenosis)were observed more than 3 months after RT.
Among the patients who survived longer than 2 years
after RT, no long-term treatment-related morbidity was
identified.
Discussion
HCC has long been one of the most serious cancers in the
world. From World Health Organization statistics in 2000,
it has been estimated that there are at least 564,000 new
Figure 2 Survival curves are shown based on solitary or multiple intrahepatic tumors (A), with or without additional organ metastasis (B),
controlled or uncontrolled primary HCC (C).
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Pacific region, HCC is a highly prevalent disease associated
with high mortality [13]. Advances in diagnostic and multi-
disciplinary applications have enhanced the possibility of
long-term survival for patients with the disease. Unfortu-
nately, the frequency of distant metastasis has concomi-
tantly increased, with major metastatic organs being the
lung, lymph node, bone, and adrenal gland. Several factors
affect metastasis, including tumor factors, tumor–stromal
interaction, inflammatory and immune reactions, and so
on. MMP-9 is crucially involved in tumor cell invasiveness
metastasis [14,15]. Radiation therapy for metastasis to
lymph node, bone, and lung is safe and effective [11,16,17].
However, with regard to RT for adrenal metastasis, there
are few published reports.
Surgical resection, TACE, and systemic chemotherapy












Liver injury 12(7/29, 5/26)*
Gastrointestinal injury 15(9/29, 6/26)*
Kidney injury 3(2/29,1/26)*
Spinal cord injury 0
*Cases of the group with two-dimensional conventional radiotherapy before 2005 a
were displayed in the brackets, and no significant difference was found between thTable 4 lists the survival outcomes of various therapies
for metastatic adrenal tumors from HCC. Because the ad-
renal gland has three feeding arteries (inferior phrenic ar-
tery, aorta, and renal artery), TACE treatment for adrenal
metastasis is technically difficult and is associated with
lower efficacy. HCC and its metastatic lesions are typically
insensitive to chemotherapy. There have been several
comparative studies of available treatment options. Park
et al. [6] reported that 30 patients with well-controlled
intrahepatic lesions and no additional organ metastasis
other than adrenal glands, received treatments such as
TACE, adrenalectomy, chemotherapy, and RT. The me-
dian survival times of patients after adrenalectomy, non-
surgical treatment, and no treatment were 21.41, 11.05,
and 5.64 months, respectively. Momoi et al. [5] analyzed
20 patients treated for adrenal metastasis of HCC by adre-
nalectomy, TACE, or PEIT and found that the median, 3D)
Grade
2 3 4
5(3/29, 2/26)* 0 0
0 0 0
0 0 0
9(4/29, 5/26)* 0 0
16(6/29, 10/26)* 5(2/29, 3/26)* 0




nd those of three-dimensional conformal or intensity-modulated radiotherapy
e two groups.
Table 4 Effect of various therapies for metastatic adrenal tumor from HCC
Treatment Author Time Case
(n)








Surgery Momoi H [5] 2002 13 8/13 have additional organs metastases. 51.3% 42%




TACE Momoi H [5] 2002 4 With tumor thrombus or additional organs metastases 5.9, 6.5, 16.1, 21.3 months
Taniai N [18] 1999 2 Single adrenal metastases and well-controlled
intrahepatic foci
Survived 3 and 8 months (still live)
PEIT Momoi H [5] 2002 4 additional organs metastases (1 case),
intrahepatic tumor (3 case)
7.6, 8.5, 21.4, 32 months
PEIT + TACE Park JS [6] 2007 19 well-controlled intrahepatic foci, no additional
organs metastases
10.5 43 0
RF+ TACE Yamakado K [19] 2009 6 intrahepatic tumor (T3), additional organs metastases
(3 cases), size of metastatic adrenal tumor (3-8 cm)
24.9
No treatment Park JS [6] 2007 6 well-controlled intrahepatic foci, no additional
organs metastases
5.6 0% -
RT Zhou LY 2014 55 Patients of liver function Child-Pugh C were excluded 13.6 58.7% 32.3%
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in cumulative survival rates was found among these three
treatment groups.
Here, we analyzed records of 55 patients treated with RT
for adrenal metastasis from HCC. To the best of our know-
ledge, it is the largest study described to date. In this co-
hort, median survival time was 13.6 months (95% CI,
10.80–16.46 months) and average survival time was
20.7 months (95% CI, 14.5–27.0 months). There was no
significant difference in median survival between the group
that received a dose of more than 54 Gy, in which median
survival was 21.3 months (95% CI, 4.7–38.0 months), and
the group that received less than 54 Gy was 12.9 months
(95% CI, 8.7–17.1 months) (P = 0.089). The tumor re-
sponse rate was 64%, which reflects the sensitivity of ad-
renal metastasis from HCC to RT.
That whether RT for adrenal metastasis could alter
the course of disease is not easily assessed, especially as
randomized studies have not been performed. Based on
present clinical data, we observed that RT could allevi-
ate pain, and influence the level of serum AFP, thereby
probably affect the progress of the disease. Definitive
guidelines for treatment of adrenal gland metastatic
tumor of HCC have not been established. It is difficult
to answer the question as to whether RT really im-
proved the survival of these patients. Greater overall
survival rates in patients treated with RT were observed
in this cohort compared with other reports, suggesting
that RT may improved the prognosis of such patients.
In a recent report from Korea [6], a median survival of
21.4 months was reported in HCC patients with adrenal
metastases treated by adrenalectomy. However, onlyfive patients receiving adrenalectomy were included in
their study.
Prognostic factors for patients with adrenal metastases
from HCC were analyzed based on tumor status, liver
function, or treatment selection. The negative prognostic
factors were identified by univariate analysis as tumor
status (including multiple intrahepatic foci, additional
organ metastases and primary HCC uncontrolled), higher
serum γ-GT and AFP levels, and a Child-Pugh classifica-
tion B. Because adrenal metastasis was rarely regarded as
the direct death cause of HCC, RT was conducted to ad-
renal lesions after their intrahepatic lesions were con-
trolled more than 2 months. A good response to RT was
found to be a favorable prognostic factor and a relatively
high dose of irradiation (≥54 Gy) tended to be a good fac-
tor in the present cohort. In selected patients based on the
prognostic factor (controlled primary HCC), high-dose RT
showed better clinical response (31.6 ± 6.5 Vs 15.3 ±
2.1 months, P < .05), though the numbers of subgroup pa-
tients were very small. In the other selected patients group
based on adrenal-only metastases, and solitary intrahepa-
tic foci, high-dose RT also seemed to demonstrate better
clinical response, but no significant differences were ob-
served probably due to the small number of patients.
Relapse of adrenal lesions after RT was found in four pa-
tients. The time of relapse ranged between 6 − 11 months
and the prescribed doses were 40 − 50 Gy. Therefore, for
some patients a relatively higher dose may be more appro-
priate. No clinical symptoms of radiation-induced neph-
ritis were observed during or after RT and cases of
increased serum levels of liver enzymes were not related
to radiation dose. New techniques being developed, such
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(SBRT), enable a higher delivery dose to tumors relative to
neighboring normal tissue. Casamassima et al. [20] and
Chawla et al. [21] adopted SBRT for treatment of metasta-
ses to the adrenal glands in well-tolerated doses (the pre-
scription dose was 36 Gy in three fractions and ranging
from 16 Gy in four fractions to 50 Gy in 10 fractions). No
consistent dose-response relationship was apparent for the
palliative RT described.
Our results indicate the possibility that appropriate
conditions of RT for adrenal metastasis from HCC may
contribute to alleviate pain symptoms. In comparison
with no treatment, there is a tendency to improved sur-
vival, especially in cases of well-controlled intrahepatic
lesions and metastasis to no additional organs other than
adrenal gland has occurred. Relatively higher doses of
RT (greater than 54 Gy) are likely to prolong patient
survival. Therefore, we propose RT as a treatment option
aimed at local control in addition to adrenalectomy.
However, a thorough evaluation of the efficacy of RT for
adrenal metastases will require further studies in larger
patient populations.Conclusions
Radiotherapy as treatment for adrenal metastases in HCC
is a good palliative therapy that is associated with reason-
able safety. Unfavorable pretreatment predictors identified
were multiple intrahepatic tumors, metastasis to additional
organ(s) and controlled primary HCC. In the RT-treated
HCC patients with adrenal metastases, intrahepatic tumor
progression was found to be the major cause of death. In
selected patients with well-controlled primary HCC pa-
tients, high-dose RT demonstrated better clinical outcome.
It appears reasonable that such patients should be consid-
ered receiving radiotherapy.Competing interest
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